



# NETWORK *Notification*

**Notice Date:** June 17, 2022  
**To:** Georgia Medicaid Providers  
**From:** CareSource  
**Subject:** Semglee Biosimilar Access for Members  
**Effective Date:** January 1, 2022

---

## Summary

The FDA-approved interchangeable biosimilar for Semglee is available for members transitioning off the non-preferred products Basaglar and Lantus. Please refer to the following National Drug Codes (NDCs) to identify preferred products with market availability.

NDC	Product Name
49502-0393-80	INSULIN GLARGINE-YFGN U100 VIAL
49502-0394-71	INSULIN GLARGINE-YFGN U100 PEN
49502-0394-75	INSULIN GLARGINE-YFGN U100 PEN

Insulin glargine-yfgn can be interchanged by the pharmacy at the point of sale for both Semglee and Lantus.

## Impact

The indicated NDCs are preferred for all Georgia Medicaid members.

## Importance

We are informing you of these product details to mitigate delays in care for members that may otherwise result from the brand Semglee shortage.

## Questions?

We recognize each patient is unique, and we appreciate your partnership in making this a successful transition. We are here to help you with any questions. Call CareSource Provider Services at **1-855-202-1058**. We are open Monday through Friday, 7 a.m. to 7 p.m. Eastern Standard Time (EST).

Thank you for being a CareSource provider.

**[New Training Available – Access and Availability Overview!](#)**

“Assignment” and “attribution” are terms that refer to the association between members and providers, but they are not interchangeable. CareSource has prepared a summary document to define these terms and describe the attribution process. Visit **CareSource.com** > Providers > Education > [Training and Events](#) to view this flier.

GA-MED-P-1064856

DCH Approval: 6/14/2022